Richard Granneman

861 total citations
18 papers, 677 citations indexed

About

Richard Granneman is a scholar working on Infectious Diseases, Virology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Richard Granneman has authored 18 papers receiving a total of 677 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Infectious Diseases, 6 papers in Virology and 6 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Richard Granneman's work include HIV/AIDS drug development and treatment (9 papers), HIV Research and Treatment (6 papers) and Pharmacological Effects and Toxicity Studies (5 papers). Richard Granneman is often cited by papers focused on HIV/AIDS drug development and treatment (9 papers), HIV Research and Treatment (6 papers) and Pharmacological Effects and Toxicity Studies (5 papers). Richard Granneman collaborates with scholars based in United States, United Kingdom and Canada. Richard Granneman's co-authors include Joseph M. Machinist, J. W. Kesterson, Emil Samara, Ann Hsu, John M. Leonard, Allen Cato, John H. Cavanaugh, David D. Ho, Harry Shi and John C. Cavanaugh and has published in prestigious journals such as Hepatology, Antimicrobial Agents and Chemotherapy and Clinical Pharmacology & Therapeutics.

In The Last Decade

Richard Granneman

16 papers receiving 657 citations

Peers

Richard Granneman

PPCH

VIROL

PMH

PHARM

A M Taburet France

Catherine Gillotin France

A J Wood United States

Line Labbé Canada

Belle L. Lee United States

Rubin Lubomirov Spain

Elizabeth K. Hussey United States

C. Locke United States

J H Lin United States

Roselyne Bidault France

A M Taburet France

Richard Granneman

239 ×0.7

236 ×0.9

PPCH

81 ×0.4

VIROL

84 ×0.6

PMH

95 ×0.8

PHARM

Citations per year, relative to Richard Granneman Richard Granneman (= 1×) peers A M Taburet

Countries citing papers authored by Richard Granneman

Since Specialization

Citations

This map shows the geographic impact of Richard Granneman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Granneman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Granneman more than expected).

Fields of papers citing papers by Richard Granneman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Granneman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Granneman. The network helps show where Richard Granneman may publish in the future.

Co-authorship network of co-authors of Richard Granneman

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Granneman. A scholar is included among the top collaborators of Richard Granneman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Granneman. Richard Granneman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Karyekar, Chetan S., Rajendra Pradhan, Qin Ji, et al.. (2005). A Phase I Multiple‐Dose Escalation Study Characterizing Pharmacokinetics and Safety of ABT‐578 in Healthy Subjects. The Journal of Clinical Pharmacology. 45(8). 910–918. 10 indexed citations

Velagapudi, Raja, et al.. (2005). Bioavailability of adalimumab following subcutaneous injections in rheumatoid arthritis patients. Clinical Pharmacology & Therapeutics. 77(2). P84–P84. 6 indexed citations

Bertz, Richard, Barry Bernstein, Yi‐Lin Chiu, et al.. (2002). Assessment of the steady-state pharmacokinetic interaction of lopinavir/ritonavir with either indinavir or saquinavir in healthy subjects. 42. 26. 5 indexed citations

Cameron, D. William, Anthony J. Japour, Yi Xu, et al.. (1999). Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS. 13(2). 213–224. 157 indexed citations

Cato, Allen, John C. Cavanaugh, Harry Shi, et al.. (1998). The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin*. Clinical Pharmacology & Therapeutics. 63(4). 414–421. 54 indexed citations

Cato, Allen, Jiang Qian, Ann Hsu, et al.. (1998). Pharmacokinetic Interaction Between Ritonavir and Didanosine When Administered Concurrently to HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 18(5). 466–472. 10 indexed citations

Cato, Allen, et al.. (1998). Multidose Pharmacokinetics of Ritonavir and Zidovudine in Human Immunodeficiency Virus-Infected Patients. Antimicrobial Agents and Chemotherapy. 42(7). 1788–1793. 19 indexed citations

Samara, Emil, Richard Granneman, Galen Witt, & John H. Cavanaugh. (1997). Effect of Valproate on the Pharmacokinetics and Pharmacodynamics of Lorazepam. The Journal of Clinical Pharmacology. 37(5). 442–450. 32 indexed citations

Samara, Emil & Richard Granneman. (1997). Role of Population Pharmacokinetics in Drug Development. Clinical Pharmacokinetics. 32(4). 294–312. 57 indexed citations

10.

Cato, Allen, Guoliang Cao, Ann Hsu, et al.. (1997). Evaluation of the effect of fluconazole on the pharmacokinetics of ritonavir.. PubMed. 25(9). 1104–6. 23 indexed citations

11.

Granneman, Richard, Patricia Wozniak, Tram Tran-Johnson, Christopher Silber, & Randall J. Mack. (1997). Population pharmacokinetics of sertindole during long-term treatment of patients with schizophrenia. Schizophrenia Research. 24(1-2). 202–202. 5 indexed citations

12.

Samara, Emil, Richard Granneman, C. Locke, Ralph A. Dean, & Tony Killian. (1996). PK and PD of Seratrodast in Patients with Moderate Asthma. Clinical Pharmacology & Therapeutics. 59(2). 208–208. 2 indexed citations

13.

Qian, Jiang, et al.. (1996). Evaluation of the Pharmacokinetic Interaction Between Ritonavir and Didanosine. Clinical Pharmacology & Therapeutics. 59(2). 144–144. 5 indexed citations

14.

Granneman, Richard, Ramanuj Achari, & Balakrishna Hosmane. (1996). PIII-60 Pharmacokinetics and Pharmacodynamics (PK/PD) of Terazosin in Hypertensive Patients. Clinical Pharmacology & Therapeutics. 59(2). 203–203.

15.

Boucher, Charles A., David D. Ho, D. Séréni, et al.. (1995). Safety, pharmacokinetics, and antiviral activity of A77003, a C2 symmetry-based human immunodeficiency virus protease inhibitor. Antimicrobial Agents and Chemotherapy. 39(7). 1559–1564. 18 indexed citations

16.

Mahr, G., et al.. (1991). The influence of temafloxacin and ciprofloxacin on the elimination of caffeine in human volunteers. 31. 197. 2 indexed citations

17.

Granneman, Richard, et al.. (1984). The Hepatotoxicity of Valproic Acid and Its Metabolites in Rats. II. Intermediary and Valproic Acid Metabolism. Hepatology. 4(6). 1153–1158. 60 indexed citations

18.

Kesterson, J. W., Richard Granneman, & Joseph M. Machinist. (1984). The Hepatotoxicity of Valproic Acid and Its Metabolites in Rats. I. Toxicologic, Biochemical and Histopathologic Studies. Hepatology. 4(6). 1143–1152. 212 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact